logo
  

Apollo Education Q3 Profit Down, Cuts FY Outlook; Shares Slip 5%

Apollo Education Group Inc. (APOL), a for-profit education provider, Monday reported a drop in profit for the third quarter as revenues continue to slip on lower student enrollments. Looking ahead, Apollo lowered its revenue guidance for the full year, sending its shares down five percent in the after hours trading.

Phoenix, Arizona-based Apollo Education's third-quarter profit dropped to $48.1 million or $0.44 per share from $66.0 million or $0.51 per share last year.

Excluding special items, adjusted earnings for the quarter were $57.5 million or $0.53 per share. Analysts polled by Thomson Reuters expected earnings of $0.47 per share for the third quarter. Analysts' estimates typically exclude special items.

Apollo's revenues for the third quarter fell to $681.5 million from $793.6 million a year earlier. Analysts had a consensus revenue estimate of $698.57 million for the third quarter.

During the quarter, new degreed enrollment at University of Phoenix slipped 13.3 percent from last year to 29,400 and degreed enrollment dropped 14.5 percent to 206,900. Apollo Education has been grappling with lower enrollments over the past several quarters.

Looking forward, the company lowered its fiscal year 2015 revenue outlook to a range of $2.60 billion to $2.62 billion from its prior outlook of $2.63 billion to $2.68 billion. Analysts currently expect the company to post revenue of $2.63 billion for the fiscal year 2015.

APOL closed Monday's trading at $15.54, down $0.81 or 4.95%, on the Nasdaq. The stock further dropped $0.79 or 5.06% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT